MCID: ACR007
MIFTS: 61

Acromegaly malady

Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases categories

Aliases & Classifications for Acromegaly

About this section
Sources:
10Disease Ontology, 11diseasecard, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 59SNOMED-CT, 42NCIt, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all sources

Aliases & Descriptions for Acromegaly:

Name: Acromegaly 10 11 45 47 12 51 65 36
Growth Hormone-Secreting Pituitary Adenoma 65
Growth Hormone Excess 45
 
Somatotroph Adenoma 45
Somatotrophinoma 65
Pituitary Giant 45


Classifications:



Characteristics (Orphanet epidemiological data):

51
acromegaly:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of); Age of onset: Adult


External Ids:

Disease Ontology10 DOID:2449
MeSH36 D000172
NCIt42 C84533
Orphanet51 963
ICD10 via Orphanet28 E22.0
MESH via Orphanet37 D000172
UMLS via Orphanet66 C0001206

Summaries for Acromegaly

About this section
NIH Rare Diseases:45 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (gh). it is most often diagnosed in middle-aged adults, although symptoms can appear at any age. signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. the condition is usually caused by benign tumors on the pituitary called adenomas. rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. when gh-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly. last updated: 4/29/2011

MalaCards based summary: Acromegaly, also known as growth hormone-secreting pituitary adenoma, is related to pituitary gland disease and hypothyroidism, and has symptoms including tall stature, abnormality of the tongue and thick lower lip vermilion. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways are Growth hormone receptor signaling and Nuclear signaling by ERBB4. The drugs bromocriptine and octreotide have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related mouse phenotypes are adipose tissue and integument.

Disease Ontology:10 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia:68 Acromegaly (/ˌækrɵˈmɛɡəli/; from Ancient Greek άκρος akros \"extreme\" or \"extremities\"... more...

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 470)
idRelated DiseaseScoreTop Affiliating Genes
1pituitary gland disease31.5GNAS, POMC, SST
2hypothyroidism30.5GH1, GHRH, PRL, TRH
3hyperprolactinemia30.4GH1, GHRH, IGF1, POMC, PRL, SST
4central nervous system primitive neuroectodermal neoplasm30.4IGF1, POMC, PRL, TRH
5diabetes insipidus30.2IGF1, IGFBP1, POMC, PRL
6pituitary adenoma, growth hormone-secreting30.1AIP, GHRH, GHRHR, GNAS, GPR101, IGF1
7multiple endocrine neoplasia 129.9GHRH, GHRHR, GNAS, MEN1, PRL, SST
8diabetes mellitus, noninsulin-dependent29.9GH1, GHR, GHRL, IGF1, IGF2, IGFBP1
9endocrine organ benign neoplasm29.9GNAS, IGFBP3, MEN1, SST
10pituitary infarct29.6GH1, IGF1, MEN1, POMC, PRL, SST
11pituitary adenoma, acth-secreting29.6AIP, GNAS, POMC, PRL, SST, SSTR2
12joint disorders29.6GHRH, IGF1, IGF2, MEN1, SST
13pheochromocytoma29.4MEN1, POMC, SST, SSTR1
14endocrine pancreas disease29.3AIP, GHRH, IGF1, MEN1, POMC, PRL
15pituitary carcinoma29.3AIP, GH1, GHRH, GNAS, IGF1, MEN1
16obesity29.0GH1, GHR, GHRH, GHRL, GNAS, IGF1
17insulin-like growth factor i10.8
18hypothalamic disease10.8
19secondary syphilis10.8
20hyperpituitarism10.8
21adenoma10.8
22pituitary tumors10.7
23pituitary adenoma10.7
24gigantism10.6
25hypothalamic neoplasm10.6
26brain cancer10.6
27central nervous system cancer10.6
28encephalopathy10.6
29pituitary apoplexy10.6
30bone cancer10.5
31marchiafava bignami disease10.5
32nervous system cancer10.5
33growth hormone deficiency10.5
34thyroiditis10.4
35multiple endocrine neoplasia10.4
36bone structure disease10.4
37neuroendocrine tumor10.4
38slow-channel congenital myasthenic syndrome10.4IGF1, IGFBP3
39prolactinoma10.4
40endocrine gland cancer10.4
41sleep apnea10.4
42mitochondrial genetic disorders10.4GH1, GHRH
43glucose metabolism disease10.3
44pancreatitis10.3
45alk-related neuroblastic tumor susceptibility10.3AIP, GNAS
46pituitary dermoid and epidermoid cysts10.3GH1, GHR, SST
47gastric cardia adenocarcinoma10.3GH1, PRL, SST
48secondary glomerular disease10.3IGF1, IGFBP3
49clear cell adenoma10.3IGF1, PRL, SST
50leptomeningeal amyloidosis10.3GH1, GHR, IGF1

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to acromegaly

Symptoms for Acromegaly

About this section

Symptoms:

 51 (show all 52)
  • broad forehead
  • coarse face
  • broad cheeks/cherub-like/cherubin face
  • prognathism/prognathia
  • broad nose/nasal bridge
  • thick lips
  • macroglossia/tongue protrusion/proeminent/hypertrophic
  • deep palmar creases
  • macrodactyly/fingers hypertrophy/megalodactyly (hand)
  • broad foot
  • abnormal sole/deep creases
  • hyperhidrosis/increased sweating
  • thick skin/pachydermia/orange skin
  • anomalies of the endocrine glands
  • hypothalamic-hypophyseal axis functional anomalies/hypopituitarism
  • articular/joint pain/arthralgia
  • hydrarthrosis/articular/joint effusion
  • osteoarthritis
  • autosomal dominant inheritance
  • tall stature/gigantism/growth acceleration
  • asthenia/fatigue/weakness
  • frontal bossing/prominent forehead
  • enlargment of jaw/large jaw
  • synophris/synophrys
  • puffy eyelids
  • anomalies of teeth and dentition
  • abnormal dentition/dental position/implantation/unerupted/dental ankylosis
  • kyphosis
  • rachidian/spine canal stenosis
  • hirsutism/hypertrichosis/increased body hair
  • dysplastic/thick/grooved fingernails
  • dysplastic/thick/grooved toenails
  • apnea/sleep apnea
  • abnormal cry/voice/phonation disorder/nasal speech
  • chronic arterial hypertension
  • metrorrhagia/menorrhagia/hemorrhagic cycles/hyper/poly/spanio/dysmenorrhea
  • diabetes mellitus
  • facial pain/cephalalgia/migraine
  • acute palsy
  • paresthesia/dysesthesia/hypoesthesia/anesthesia/numbness
  • humour troubles/anxiety/depression/apathy/euphoria/irritability
  • pituitary/hypophyseal neoplasm/tumor/carcinoma/cancer
  • acne/acnea
  • diffuse/generalised skin hyperpigmentation/melanoderma
  • acanthosis nigricans
  • mitral valve prolapse/incompetence/insufficiency/regurgitation/ring anomaly
  • cardiomyopathy/hypertrophic/dilated
  • pollakiuria/polyuria/dysuria/anuria/acute urine retention/oliguria
  • functional anomalies of the genital system
  • impotence/painful erection/priapism/erection troubles
  • galactorrhea
  • somnolence/hypersomnia/parasomnia

HPO human phenotypes related to Acromegaly:

(show all 45)
id Description Frequency HPO Source Accession
1 tall stature hallmark (90%) HP:0000098
2 abnormality of the tongue hallmark (90%) HP:0000157
3 thick lower lip vermilion hallmark (90%) HP:0000179
4 coarse facial features hallmark (90%) HP:0000280
5 full cheeks hallmark (90%) HP:0000293
6 mandibular prognathia hallmark (90%) HP:0000303
7 broad forehead hallmark (90%) HP:0000337
8 abnormality of the nose hallmark (90%) HP:0000366
9 anterior hypopituitarism hallmark (90%) HP:0000830
10 hyperhidrosis hallmark (90%) HP:0000975
11 joint swelling hallmark (90%) HP:0001386
12 broad foot hallmark (90%) HP:0001769
13 deep plantar creases hallmark (90%) HP:0001869
14 osteoarthritis hallmark (90%) HP:0002758
15 arthralgia hallmark (90%) HP:0002829
16 deep palmar crease hallmark (90%) HP:0006191
17 macrodactyly of finger hallmark (90%) HP:0100746
18 abnormality of the menstrual cycle typical (50%) HP:0000140
19 abnormality of the teeth typical (50%) HP:0000164
20 synophrys typical (50%) HP:0000664
21 behavioral abnormality typical (50%) HP:0000708
22 diabetes mellitus typical (50%) HP:0000819
23 hypertension typical (50%) HP:0000822
24 abnormality of the fingernails typical (50%) HP:0001231
25 abnormality of the voice typical (50%) HP:0001608
26 frontal bossing typical (50%) HP:0002007
27 migraine typical (50%) HP:0002076
28 apnea typical (50%) HP:0002104
29 kyphosis typical (50%) HP:0002808
30 paresthesia typical (50%) HP:0003401
31 spinal canal stenosis typical (50%) HP:0003416
32 abnormality of the toenails typical (50%) HP:0008388
33 cerebral palsy typical (50%) HP:0100021
34 palpebral edema typical (50%) HP:0100540
35 neoplasm of the endocrine system typical (50%) HP:0100568
36 abnormality of reproductive system physiology occasional (7.5%) HP:0000080
37 acanthosis nigricans occasional (7.5%) HP:0000956
38 acne occasional (7.5%) HP:0001061
39 abnormality of the mitral valve occasional (7.5%) HP:0001633
40 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
41 reduced consciousness/confusion occasional (7.5%) HP:0004372
42 generalized hyperpigmentation occasional (7.5%) HP:0007440
43 abnormal renal physiology occasional (7.5%) HP:0012211
44 erectile abnormalities occasional (7.5%) HP:0100639
45 galactorrhea occasional (7.5%) HP:0100829

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2281462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Octreotideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 119183150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
3
CabergolineapprovedPhase 44281409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
4
Sitagliptinapproved, investigationalPhase 4381486460-32-64369359
Synonyms:
(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
(2R)-4-OXO-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
(3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
1x70
486460-32-6
AB1004599
AC1N9ZYR
BRD-K19416115-001-01-2
BSPBio_002262
CHEBI:40237
CHEMBL1422
CID4369359
D08516
DB01261
 
DB07214
HMS2093F20
HSDB 7516
Janumet
Januvia
Januvia (merck & Co.)
LS-187389
MK-0431
MolPort-003-666-756
Sitagliptan
Sitagliptin
Sitagliptin (Prop.INN)
Sitagliptin phosphate
Sitagliptina
Sitagliptine
Sitagliptinum
UNII-QFP0P1DV7Z
Xelevia
5
ZincapprovedPhase 414047440-66-623994, 32051
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
6
MetforminapprovedPhase 41573657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
7
LiraglutideapprovedPhase 4257204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
 
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
Saxenda
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
8
LactitolPhase 4, Phase 3, Phase 1313585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
9Insulin, Globin ZincPhase 4, Phase 3, Phase 24069
10Dopamine AgonistsPhase 4476
11AngiopeptinPhase 4, Phase 3, Phase 2, Phase 166
12lanreotidePhase 4, Phase 3, Phase 2, Phase 166
13insulinPhase 4, Phase 3, Phase 24069
14
SomatostatinPhase 4, Phase 3, Phase 2, Phase 114151110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
15Complement Factor IPhase 4, Phase 336
16
Mannitolapproved, investigationalPhase 322069-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
17Carboxymethylcellulose SodiumPhase 397
18RadiopharmaceuticalsPhase 3345
19EdotreotidePhase 320
20
DimenhydrinateapprovedPhase 238523-87-5441281
Synonyms:
(O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide
2-benzhydryloxyethyl(dimethyl)azanium
8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
8-chloro-1,3-dimethyl-2-oxopurin-6-olate
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
AC1L9AVV
Airmit Ace
Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
CAS-523-87-5
CHEBI:4604
CID441281
Colace
D00520
DB00985
Dimenhidrinato
Dimenhydrinate
Dimenhydrinate (JP15/USP/INN)
Dimenhydrinatum
Diphenhydramine 8-chlorotheophyllinate
Diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Diphenhydrinate
 
Dosolax
Dramamine (TN)
Dramamine For Kids
Dramamine Orange
Dramamine Original Formula
Driminate
HMS1568F12
Motion Sickness
Motion Sickness Original Formula
Motion Sickness Original formula
Motion Sickness Relief
Motion Sickness Relief Original Formula
N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
NCGC00017026-01
Novamine
O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Original Formula Motion Sickness Relief
Pac-kit Motion Sickness
Physicianscare Dimenhydrinate Motion Sickness Relief
Prestwick_892
Soflax
Travel Ease
Travel Sickness
Wal-dram
beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
21
Tadalafilapproved, investigationalPhase 2137171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
22ZuclomiphenePhase 2147
23EnclomiphenePhase 2147
24ClomiphenePhase 2147
25Ethinyl estradiol, levonorgestrel drug combinationPhase 266
26Phosphodiesterase 5 InhibitorsPhase 2518
27
Citric AcidnutraceuticalPhase 278477-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
28CitrateNutraceuticalPhase 2784
29
Furosemideapproved15854-31-93440
Synonyms:
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
AKOS000266625
ARONIS24304
Acetic acid potassium salt
Aisemide
Aldalix
Aldic
Aluzine
Anfuramaide
Apo-Frusemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
BIDD:GT0139
BPBio1_000443
BRD-K78010432-001-05-8
BRN 0840915
BSPBio_000401
BSPBio_002054
Beronald
Bio-0044
Bioretic
Bristab
Bristurin
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
CHEBI:47426
CHEMBL35
CID3440
CPD000058202
Cetasix
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic Salt
Diuretic salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
EINECS 200-203-6
Edemid
Edenol
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
FUN
FUROSEMIDE USP
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
Furo-Basan
Furo-Puren
Furo-puren
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide M.D.
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide Monohydrochloride
Furosemide Monosodium Salt
Furosemide [USAN:INN:JAN]
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
 
Golan
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
HSDB 3086
Hissuflux
Hoe-058A
Hydol
Hydrenox
Hydrex
Hydro
Hydro-Rapid
Hydro-rapid
Hydroled
I04-0179
IDI1_000575
Impugan
Jenafusid
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Katlex
Kofuzon
Kolkin
Kutrix
LB 502
LB-502
LS-204
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (TN)
Lasix (tn)
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
Leodrine
Less Diur
Liside
Logirene
Lowpston
Lowpstron
Luscek
MLS001066374
MLS001306403
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
Moilarorin
MolPort-001-641-065
Myrosemide
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
NINDS_000575
NSC 269420
NSC269420
Nadis
Nelsix
Neo-Renal
Neo-renal
Nephron
Nicorol
Novosemide
Octan Draselny
Octan draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall A
Prefemin
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Prestwick_752
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
SAM002264614
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
SPECTRUM1500310
STK177334
Sal Diureticum
Sal diureticum
Salinex
Salix
Salix (brand of furosemide)
Salurex
Salurid
Saluron
Seguril
Selectofur
Sigasalur
Sisuril
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spectrum_001100
Spirofur
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
fulvamide
furosemide
furosemide ''mita''
less Diur
30
Amilorideapproved452016-88-816231
Synonyms:
17440-83-4 (hydrochloride)
1f5l
2016-88-8 (anhydrous hydrochloride)
2609-46-3
3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide
3,5-Diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide
3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
AB00053415
AC-13631
AC1L27IZ
AC1Q3POC
AMILORIDE
AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8))
Amiclaran
Amiclaran (TN)
Amikal (Hydrochloride dihydrate)
Amilorid
Amilorida
Amilorida [INN-Spanish]
Amiloride
Amiloride (INN)
Amiloride HCL
Amiloride Hydrochloride
Amiloride [INN:BAN]
Amiloride hydrochloride hydrate
Amiloridum
Amiloridum [INN-Latin]
Amipramidin
Amipramidine
Amipramizid
Amipramizide
Amiprazidine
Amyloride
BCBcMAP01_000101
BIDD:GT0466
BPBio1_000015
BRD-K97181089-003-02-3
BRD-K97181089-310-03-0
BSPBio_000013
BSPBio_001572
BSPBio_001826
Bio1_000359
Bio1_000848
Bio1_001337
Bio2_000292
Bio2_000772
C06821
C6H8ClN7O
CCRIS 6545
CHEBI:2639
CHEMBL945
CID16231
CPD-10324
D07447
DB00594
Diurex
DivK1c_000182
 
EINECS 220-024-7
Guanamprazin
Guanamprazine
HMS1791O14
HMS1989O14
HMS2089H05
IDI1_000182
IDI1_034042
KBio1_000182
KBio2_000292
KBio2_000394
KBio2_002860
KBio2_002962
KBio2_005428
KBio2_005530
KBio3_000583
KBio3_000584
KBio3_001326
KBioGR_000292
KBioGR_000544
KBioSS_000292
KBioSS_000394
LS-1094
Lopac-A-7410
Lopac0_000111
MK-870 (Hydrochloride dihydrate)
MLS000758249
MLS001060798
Midamor
Midamor (Hydrochloride dihydrate)
MolPort-005-934-472
MolPort-005-937-651
N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide
N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid
NCGC00015089-01
NCGC00015089-02
NCGC00015089-12
NCGC00024443-02
NCGC00024443-05
NCGC00024443-06
NCGC00024443-07
NCGC00024443-09
NINDS_000182
Prestwick0_000007
Prestwick1_000007
Prestwick2_000007
Prestwick3_000007
Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride
SMR000449325
SMR000486264
SPBio_000136
SPBio_001934
ST079279
Spectrum2_000118
Spectrum3_000293
Spectrum4_000132
Spectrum5_000776
Spectrum_000034
Tocris-0890
UNII-7DZO8EB0Z3
ZINC04340269
31
Benzocaineapproved15361994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
20/20 Topical Anesthetic
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Alcohol Prep Pads
Allegenal-m
Alpha-caine Topical Anesthetic
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anbesol Jr
Anbesol Maximum Strength
Anbesol Regular Strength
Anestenka
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthetic
Anesthone
Atopalm Oral Pain Relief
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Baby Anestenka
Baby Sensigel
Baby Sensigel Night Time Formula
Baby Teething Oral Pain Reliever
Bactimicina For Sore Throat
Bencocaine Topical Anesthetic
Bensokain
Benz O Sthetic
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzodent
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
Boil Ease
Boy Butter Desensitizing Lubricant
Boy Butter Extreme Desensitizing Lubricant
Boy Butter Extreme H2O Desensitizing Lubricant
Brace Relief
Budpak Baby Teething Oral Pain Reliever
Budpak Oral Maximum Strength
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Carmex Cold Sore Treatment External Analgesic
Caswell No. 430A
Cepacol Fizzlers
Cepacol Sensations Hydra
Cepacol Sensations Sore Throat Hydra citrus splash
Cepacol Sensations Warming
Certus Sting Relief Prep Pad
Chloraseptic
Chloraseptic Warming Sore Throat
Colgate Orabase
Comfortcaine Topical Anesthetic
Cvs Fast Acting Baby Teething
Cvs Maximum Strength
Cvs Maximum Strength Boil Relief
Cvs Oral Anesthetic
Cvs Pharmacy Instant Toothache
Cvs Pharmacy Maximum Strength
Cvs Pharmacy Mouth Sore Gel
Cvs Pharmacy Nighttime Oral Pain Relief
D001566
D00552
DB01086
Dental Relief
Dentek Instant Pain Relief Maximum Strength
Dermoplast
Diet Ayds
DivK1c_000932
Dollar General Toothache Relief
Dukal Sting Relief Pad
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Finafta Baby
Finafta MultiOral
Formate, Benzocaine
Gelato Topical Anesthetic
Good Neighbor Pain Relief
Goodsense Oral Pain Relief
Gps Topical Anesthetic
Gumnumb Topical Anesthetic
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Heb Severe Toothache
Herbasoul Male Genital Desensitizer Cream
 
Hurricaine
Hurricaine Topical Anesthetic
Hurricaine Topical Anesthetic Gel
Hurricaine Topical Anesthetic Liquid
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
Insect Bite Relief
Instant Toothache Pain Relief
Intense Cvs Intense Toothache
Iodent Maximum Strength Oral Analgesic
Ismile Topical Anesthetic
Jianze Sting Relief Pads
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Kank-a Mouth Pain
Keloform
Kmart Smart Sense
Kroger Toothache Pain Relief
LS-35847
Leader Oral Analgesic
Little Colds Sore Throat Relief Melt Aways
MLS001331704
MLS002153970
Makesense Junior Pain Relief
Makesense Pain Relief
Male Desensitizer Pleasure Balm
Mandelay Male Genital Desensitizer
Mark 3
Methanesulfonate, Benzocaine
MolPort-000-871-526
Mouth Sore Medication
Mouth Sore Relief Applicator
Mouth Sore Relief Professional Strength
My Fair Baby Instant Pain Relief
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Nene Dente
Norcain
Norcaine
Norcainum
Opahl
Opahl Dye Free
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orajel For All Mouth Sores Maximum Strength
Orajel For Cold Sores
Orajel For Toothache Maximum Strength
Orajel Instant Pain Relief Maximum Strength
Orajel Instant Pain Relief Regular Strength
Orajel Instant Relief For Teething Pain
Orajel Instant Relief For Teething Pain Cooling Cucumber
Orajel Instant Relief For Teething Pain Daytime Nighttime Twin Pack
Orajel Instant Relief For Teething Pain Longer Lasting
Orajel Maximum Strength
Orajel Nighttime Instant Relief For Teething Pain Longer Lasting Extra Strength
Orajel Severe Toothache Maximum Strength Fast-Acting Formula
Oral Analgesic Maximum Strength
Oral B Instant Pain Relief
Oral Gel Maximum Strength
Oral Pain Relief Anesthetic Anesthetic
Oral Pain Reliever
Oralabs Cold Sore Treatment
Orthesin
Otocain
Outgro
Pac-dent Top Gel
Pain Relief
Pain Relief Alcohol Swabs
Parathesin
Parathesin (TN)
Parathesine
Physicians Care Sting Relief Pad
Pleasure Balm Kama Sutra
Preboost
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
Purelife Topical Anesthetic
Quality Choice Maximum Strength Oral Pain Relieving
Red Cross Oral Pain Relief
Rexall Maximum Strength
Rite Aid Baby Care
Rite Aid Liquid Anesthetic Oral Pain Relief
Rite Aid Maximum Strength
Rite Aid Oral Pain Reliever
Rite Aid Professional Strength
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Sally Hansen Ouch-relief Numbing Wipes
Sally Hansen Ouch-relief Wax Kit
Sally Hansen Ouch-relief Wax Strip Kit
Sensigel
Severe Oral Pain Reliever
Sheffield Baby Teething Gel
Sheffield Pain Relief
Shunga Male Genital Desensitizer
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Sting Relief Medicated Pad
Sting Relief Pads
Tanac
Terrasil Boil Pain Relief
Tiger Supply Inc Topical Anesthetic
Top Quality Mfg. Topical Anesthetic
Topcaine
Topcare Maximum Strength
Topical Anesthetic Banana
Topical Anesthetic Bubble Gum
Topical Anesthetic Cherry
Topical Anesthetic Mint
Topical Anesthetic Pina Colada
Topical Anesthetic Raspberry
Topical Anesthetic Strawberry
UNII-U3RSY48JW5
Ultracare Anesthetic Bubble Gum
Ultracare Anesthetic Butter Rum
Ultracare Anesthetic Creme de Menthe
Ultracare Anesthetic Pina Colada
Ultracare Anesthetic Walterberry
WLN: ZR DVO2
Walgreens Baby Teething
Walgreens Intense Toothache
Walgreens Maximum Strength
Walgreens Pain Relieving For Boils
Walgreens Severe Oral Pain Reliever
Walgreens Severe Toothache Relief
Winco Foods Maximum Strength Oral Analgesic
ZINC12358719
Zilactin-b
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
32
Ursodeoxycholic acidapproved, investigational74128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
ISO-URSODEOXYCHOLIC ACID
 
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol Tablets, 250 mg
Ursodiol Tablets, 500 mg
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
33Natriuretic Peptide, Brain167
34Growth Hormone-Releasing Hormone23
35Calcium, Dietary3529
36tannic acidNutraceutical1536

Interventional clinical trials:

(show top 50)    (show all 136)
idNameStatusNCT IDPhase
1Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
2Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
3Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
4Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
5Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
6Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
7Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793Phase 4
8Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
9Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
10Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4
11A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
12A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520Phase 4
13Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4
14Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
15Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
16Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227Phase 4
17Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Phase 4
18Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
19Surgical Debulking of Pituitary AdenomasCompletedNCT01371643Phase 4
20Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantRecruitingNCT00552851Phase 4
21Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyRecruitingNCT02115906Phase 4
22Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesRecruitingNCT02427295Phase 4
23Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
24Pasireotide LAR and Pegvisomant Study in AcromegalyRecruitingNCT02668172Phase 4
25Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)RecruitingNCT00915954Phase 4
26A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.RecruitingNCT01861717Phase 4
27Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
28Treatment of the Dumping Syndrome With Lanreotide Autogel®RecruitingNCT00543179Phase 4
29Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetActive, not recruitingNCT01618513Phase 4
30Effects of Sandostatin LAR® in AcromegalyActive, not recruitingNCT01424241Phase 4
31Octreotide Efficacy and Safety in First-line Acromegalic PatientsSuspendedNCT00171886Phase 4
32Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
33Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
34Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
35Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3
36Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
37Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3
38Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3
39Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3
40Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
41Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
42Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
43Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
44Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
45Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
46Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2, Phase 3
47A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
48Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesRecruitingNCT02354508Phase 3
49Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyRecruitingNCT02685709Phase 3
50Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyRecruitingNCT02493517Phase 3

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: Acromegaly

Genetic Tests for Acromegaly

About this section

Anatomical Context for Acromegaly

About this section

MalaCards organs/tissues related to Acromegaly:

33
Pituitary, Bone, Testes, Brain, Pancreas, Lung, Skin

FMA organs/tissues related to Acromegaly:

16
Limb

Animal Models for Acromegaly or affiliated genes

About this section

MGI Mouse Phenotypes related to Acromegaly:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.9GH1, GHR, GHRHR, GHRL, GNAS, IGF1
2MP:00107718.7AIP, GHR, GHRHR, GNAS, IGF1, IGF2
3MP:00053708.1AIP, GH1, GHR, GHRH, GNAS, IGF2
4MP:00053898.0GH1, GHR, GHRH, GHRHR, IGF1, IGF2
5MP:00053877.5GHR, GHRH, GHRHR, GNAS, IGF1, IGF2
6MP:00053867.5GHR, GHRHR, GHRL, GNAS, IGF2, IGFBP3
7MP:00053787.3AIP, GH1, GHR, GHRH, GHRHR, GNAS
8MP:00036316.8GH1, GHR, GHRH, GHRHR, GNAS, IGF1
9MP:00053796.7AIP, GH1, GHR, GHRH, GHRHR, GHRL
10MP:00053765.8AIP, GH1, GHR, GHRH, GHRHR, GHRL

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50)    (show all 1395)
idTitleAuthorsYear
1
Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. (26530355)
2015
2
Tear Osmolarity and Tear Function Changes in Patients with Acromegaly. (25310803)
2014
3
Acromegaly: assessing the disorder and navigating therapeutic options for treatment. (25374336)
2014
4
A consensus on the diagnosis and treatment of acromegaly complications. (22903574)
2013
5
Acromegaly and oxidative stress: impact on endothelial dysfunction and atherosclerosis. (23608960)
2013
6
Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naA^ve acromegaly. (23593161)
2013
7
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. (23529827)
2013
8
A case of acromegaly complicated with diabetic ketoacidosis, pituitary apoplexy, and lymphoma. (24296058)
2013
9
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. (21744088)
2012
10
Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. (22613412)
2012
11
Invasive sphenocavernous aspergilloma complicating an operated case of acromegaly. (23984200)
2011
12
Acromegaly caused by ectopic growth hormone-releasing hormone production from a bronchial carcinoid tumor. (21480145)
2011
13
Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. (20813787)
2010
14
N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly. (20930495)
2010
15
Lanreotide for the treatment of acromegaly. (19533047)
2009
16
The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. (19109045)
2009
17
Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. (18418712)
2008
18
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? (18000757)
2008
19
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. (19016004)
2008
20
Acromegaly. (18578866)
2008
21
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. (17047390)
2006
22
Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. (16809928)
2006
23
Predictors and rates of treatment-resistant tumor growth in acromegaly. (16061822)
2005
24
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. (16076947)
2005
25
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. (15585549)
2005
26
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. (16159936)
2005
27
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. (15827109)
2005
28
GH and mortality in acromegaly. (16625851)
2005
29
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. (16046586)
2005
30
Cardiovascular complications in acromegaly. (15282442)
2004
31
Pegvisomant: a new treatment modality for acromegaly. (16982575)
2004
32
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. (14609359)
2003
33
Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly. (12029573)
2002
34
Experience with pegvisomant in the treatment of acromegaly. (11527081)
2001
35
Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. (11083070)
2000
36
Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. (11788011)
2000
37
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. (8548933)
1995
38
Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. (7750196)
1995
39
The magnitude of growth hormone elevation is related with the proportion of monomeric form in acromegaly. (8845645)
1995
40
Acute effects of a single administration of dexamethasone on basal and growth hormone-releasing hormone stimulated GH secretion in acromegaly. (8137516)
1994
41
Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values. (8325938)
1993
42
Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly. (7680832)
1993
43
Pituitary adenomas of patients with acromegaly express thyrotropin- releasing hormone receptor messenger RNA: cloning and functional expression of the human thyrotropin-releasing hormone receptor gene. (8396925)
1993
44
Clinical experience of octreotide in the treatment of acromegaly. (1358345)
1992
45
A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor. (1506622)
1992
46
Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. (1563080)
1992
47
The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly]. (1674920)
1991
48
Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly. (2273211)
1990
49
Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. (2229278)
1990
50
Somatostatin analog treatment of acromegaly: new aspects. (2900190)
1988

Variations for Acromegaly

About this section

Clinvar genetic disease variations for Acromegaly:

5 (show all 61)
id Gene Variation Type Significance SNP ID Assembly Location
1GNASNM_000516.5(GNAS): c.601C> T (p.Arg201Cys)single nucleotide variantPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
2GNASNM_000516.5(GNAS): c.602G> A (p.Arg201His)single nucleotide variantPathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
3GNASNM_000516.5(GNAS): c.680A> G (p.Gln227Arg)single nucleotide variantPathogenicrs121913494GRCh37Chr 20, 57484596: 57484596
4GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)single nucleotide variantPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
5GPR101NM_054021.1(GPR101): c.924G> C (p.Glu308Asp)single nucleotide variantPathogenicrs73637412GRCh38Chr X, 137030751: 137030751
6GPR101NP_473362.1: p.Asp366Gluundetermined variantPathogenic
7AIPNM_003977.2(AIP): c.-1212_279+578deldeletionLikely pathogenicGRCh37Chr 11, 67249418: 67255234
8AIPNM_003977.2(AIP): c.(?_1)_(*_?)deletionLikely pathogenic
9AIPNM_003977.3(AIP): c.100-1025_279+357del1562deletionLikely pathogenicGRCh37Chr 11, 67253452: 67255013
10AIPNM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del)deletionLikely pathogenicrs267606537GRCh37Chr 11, 67254515: 67254538
11AIPNM_003977.3(AIP): c.166C> A (p.Arg56Ser)single nucleotide variantLikely pathogenicrs267606538GRCh37Chr 11, 67254543: 67254543
12AIPNM_003977.3(AIP): c.174G> C (p.Lys58Asn)single nucleotide variantLikely pathogenicrs267606539GRCh37Chr 11, 67254551: 67254551
13AIPNM_003977.3(AIP): c.241C> T (p.Arg81Ter)single nucleotide variantPathogenicrs267606541GRCh37Chr 11, 67254618: 67254618
14AIPNM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs)deletionLikely pathogenicrs267606542GRCh37Chr 11, 67254621: 67254625
15AIPNM_003977.3(AIP): c.249G> T (p.Gly83=)single nucleotide variantLikely pathogenicrs104895072GRCh37Chr 11, 67254626: 67254626
16AIPNM_003977.3(AIP): c.250G> A (p.Glu84Lys)single nucleotide variantLikely pathogenicrs267606543GRCh37Chr 11, 67254627: 67254627
17AIPNM_003977.3(AIP): c.280-1G> Asingle nucleotide variantLikely pathogenicrs267606544GRCh37Chr 11, 67256737: 67256737
18AIPNM_003977.3(AIP): c.286_287delGT (p.Val96Profs)deletionLikely pathogenicrs267606545GRCh37Chr 11, 67256744: 67256745
19AIPNM_003977.3(AIP): c.2T> C (p.Met1Thr)single nucleotide variantLikely pathogenicrs267606546GRCh37Chr 11, 67250631: 67250631
20AIPNM_003977.3(AIP): c.308A> G (p.Lys103Arg)single nucleotide variantLikely pathogenicrs267606548GRCh37Chr 11, 67256766: 67256766
21AIPNM_003977.3(AIP): c.350delG (p.Gly117Alafs)deletionLikely pathogenicrs267606549GRCh37Chr 11, 67256808: 67256808
22AIPNM_003977.3(AIP): c.3_4insC (p.Ala2Argfs)insertionLikely pathogenicrs267606547GRCh37Chr 11, 67250632: 67250633
23AIPNM_003977.3(AIP): c.404delA (p.His135Leufs)deletionLikely pathogenicrs267606551GRCh37Chr 11, 67256862: 67256862
24AIPNM_003977.3(AIP): c.424C> T (p.Gln142Ter)single nucleotide variantLikely pathogenicrs267606552GRCh37Chr 11, 67256882: 67256882
25AIPNM_003977.3(AIP): c.468+1G> Asingle nucleotide variantLikely pathogenicrs267606554GRCh37Chr 11, 67256927: 67256927
26AIPNM_003977.3(AIP): c.469-2A> Gsingle nucleotide variantLikely pathogenicrs267606556GRCh37Chr 11, 67257507: 67257507
27AIPNM_003977.3(AIP): c.490C> T (p.Gln164Ter)single nucleotide variantLikely pathogenicrs104895073GRCh37Chr 11, 67257530: 67257530
28AIPNM_003977.3(AIP): c.500delC (p.Pro167Hisfs)deletionLikely pathogenicrs267606557GRCh37Chr 11, 67257540: 67257540
29AIPNM_003977.3(AIP): c.517_521delGAAGA (p.Glu174Glyfs)deletionLikely pathogenicrs267606558GRCh37Chr 11, 67257557: 67257561
30AIPNM_003977.3(AIP): c.550C> T (p.Gln184Ter)single nucleotide variantLikely pathogenicrs267606560GRCh37Chr 11, 67257590: 67257590
31AIPNM_003977.3(AIP): c.584T> C (p.Val195Ala)single nucleotide variantLikely pathogenicrs267606561GRCh37Chr 11, 67257624: 67257624
32AIPNM_003977.3(AIP): c.591G> A (p.Glu197=)single nucleotide variantLikely pathogenicrs202006716GRCh37Chr 11, 67257631: 67257631
33AIPNM_003977.3(AIP): c.601A> T (p.Lys201Ter)single nucleotide variantLikely pathogenicrs267606563GRCh37Chr 11, 67257641: 67257641
34AIPNM_003977.3(AIP): c.646G> T (p.Glu216Ter)single nucleotide variantLikely pathogenicrs267606565GRCh37Chr 11, 67257787: 67257787
35AIPNM_003977.3(AIP): c.649C> T (p.Gln217Ter)single nucleotide variantLikely pathogenicrs267606566GRCh37Chr 11, 67257790: 67257790
36AIPNM_003977.3(AIP): c.662dupC (p.Glu222Terfs)duplicationLikely pathogenicrs104895075GRCh37Chr 11, 67257803: 67257803
37AIPNM_003977.3(AIP): c.70G> T (p.Glu24Ter)single nucleotide variantLikely pathogenicrs267606568GRCh37Chr 11, 67250699: 67250699
38AIPNM_003977.3(AIP): c.713G> A (p.Cys238Tyr)single nucleotide variantLikely pathogenicrs267606569GRCh37Chr 11, 67257854: 67257854
39AIPNM_003977.3(AIP): c.715C> T (p.Gln239Ter)single nucleotide variantLikely pathogenicrs267606571GRCh37Chr 11, 67257856: 67257856
40AIPNM_003977.3(AIP): c.721A> G (p.Lys241Glu)single nucleotide variantPathogenicrs267606573GRCh37Chr 11, 67257862: 67257862
41AIPNM_003977.3(AIP): c.721A> T (p.Lys241Ter)single nucleotide variantLikely pathogenicrs267606573GRCh37Chr 11, 67257862: 67257862
42AIPNM_003977.3(AIP): c.742_744delTAC (p.Tyr248del)deletionLikely pathogenicrs267606574GRCh37Chr 11, 67257883: 67257885
43AIPNM_003977.3(AIP): c.74_81delTCCCGGACins7indelLikely pathogenicrs104895074GRCh37Chr 11, 67250703: 67250710
44AIPNM_003977.3(AIP): c.769A> G (p.Ile257Val)single nucleotide variantLikely pathogenicrs267606575GRCh37Chr 11, 67257910: 67257910
45AIPNM_003977.3(AIP): c.803A> G (p.Tyr268Cys)single nucleotide variantLikely pathogenicrs267606577GRCh37Chr 11, 67258274: 67258274
46AIPNM_003977.3(AIP)duplicationPathogenicrs267606578GRCh37Chr 11, 67258276: 67258296
47AIPNM_003977.3(AIP): c.807C> T (p.Phe269=)single nucleotide variantPathogenicrs139407567GRCh37Chr 11, 67258278: 67258278
48AIPNM_003977.3(AIP): c.811C> T (p.Arg271Trp)single nucleotide variantPathogenicrs267606579GRCh37Chr 11, 67258282: 67258282
49AIPNM_003977.3(AIP): c.829G> C (p.Ala277Pro)single nucleotide variantLikely pathogenicrs267606581GRCh37Chr 11, 67258300: 67258300
50AIPNM_003977.3(AIP): c.854_857delAGGC (p.Gln285Leufs)deletionLikely pathogenicrs267606582GRCh37Chr 11, 67258325: 67258328
51AIPNM_003977.3(AIP): c.919dupC (p.Arg307Profs)duplicationLikely pathogenicrs267606589GRCh37Chr 11, 67258390: 67258390
52AIPNM_003977.3(AIP): c.-125-95G> Asingle nucleotide variantLikely pathogenicrs267606540GRCh37Chr 11, 67250410: 67250410
53AIPNM_003977.3(AIP): c.880_891delCTGGACCCAGCC (p.Asp295_Leu298del)deletionLikely pathogenicrs267606585GRCh37Chr 11, 67258351: 67258362
54AIPNM_003977.3(AIP): c.40C> T (p.Gln14Ter)single nucleotide variantPathogenicrs104894194GRCh37Chr 11, 67250669: 67250669
55AIPNM_003977.3(AIP): c.469-1G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs267606555GRCh37Chr 11, 67257508: 67257508
56AIPNM_003977.3(AIP): c.910C> T (p.Arg304Ter)single nucleotide variantPathogenicrs104894195GRCh37Chr 11, 67258381: 67258381
57AIPNM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del)deletionLikely pathogenic, Pathogenicrs267606567GRCh37Chr 11, 67250695: 67250700
58AIPNM_003977.3(AIP): c.824dupA (p.His275Glnfs)duplicationLikely pathogenic, Pathogenicrs267606580GRCh37Chr 11, 67258295: 67258295
59AIPNM_003977.3(AIP): c.542delT (p.Ile182Serfs)deletionLikely pathogenic, Pathogenicrs267606559GRCh37Chr 11, 67257582: 67257582
60AIPNM_003977.3(AIP): c.804C> A (p.Tyr268Ter)single nucleotide variantLikely pathogenic, Pathogenicrs121908356GRCh37Chr 11, 67258275: 67258275
61AIPNM_003977.3(AIP): c.64C> T (p.Arg22Ter)single nucleotide variantLikely pathogenic, Pathogenicrs121908357GRCh37Chr 11, 67250693: 67250693

Cosmic variations for Acromegaly:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
127899GNASpituitary,NS,adenoma,GH3
227889GNASpituitary,NS,adenoma,GH3
349087GNASpituitary,NS,adenoma,GH3
427895GNASpituitary,NS,adenoma,GH3
527893GNASpituitary,NS,adenoma,GH3
627887GNASpituitary,NS,adenoma,GH3
7483HRASpituitary,NS,adenoma,GH3

Expression for genes affiliated with Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.

Pathways for genes affiliated with Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.9GH1, GHR, PRL
2
Show member pathways
9.9GH1, GHR, PRL
39.5GH1, GHR, IGF1, IGF2
4
Show member pathways
9.5GH1, GHRL, IGF1, POMC
59.4GHRH, GHRHR, GNAS, POMC
69.4IGF1, IGF2, IGFBP1, IGFBP3
7
Show member pathways
9.4IGF1, IGF2, IGFBP1, IGFBP3
8
Show member pathways
9.0GHRL, GNAS, SSTR1, SSTR2, SSTR5
9
Show member pathways
7.1GH1, GHR, GHRH, GHRHR, GHRL, GNAS
10
Show member pathways
6.2GH1, GHR, GHRH, GHRHR, GHRL, GNAS

GO Terms for genes affiliated with Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor binding protein complexGO:001694210.8IGF1, IGFBP3
2insulin-like growth factor ternary complexGO:004256710.8IGF1, IGFBP3
3secretory granule lumenGO:003477410.3GHRL, POMC
4secretory granuleGO:003014110.0GHRHR, POMC, TRH
5extracellular spaceGO:00056158.0GH1, GHR, GHRH, GHRL, IGF1, IGF2
6extracellular regionGO:00055767.1GH1, GHR, GHRH, GHRL, GNAS, IGF1

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 34)
idNameGO IDScoreTop Affiliating Genes
1adenylate cyclase-activating adrenergic receptor signaling pathwayGO:007188010.8GNAS, GPR101
2insulin-like growth factor receptor signaling pathwayGO:004800910.7GHR, IGF1
3growth hormone receptor signaling pathwayGO:006039610.7GH1, GHR
4positive regulation of glycogen biosynthetic processGO:004572510.6IGF1, IGF2
5exocrine pancreas developmentGO:003101710.6IGF1, IGF2
6JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.5GH1, GHR, PRL
7positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5GH1, GHR, IGF1
8positive regulation of hormone secretionGO:004688710.5GHRH, GHRHR
9adenohypophysis developmentGO:002198410.5GHRH, GHRHR
10water homeostasisGO:003010410.5GHRHR, IGF1
11cellular response to glucocorticoid stimulusGO:007138510.4SSTR2, SSTR5
12positive regulation of JAK-STAT cascadeGO:004642710.3GH1, GHR, PRL
13regulation of protein metabolic processGO:005124610.3GHRHR, IGF1
14regulation of insulin-like growth factor receptor signaling pathwayGO:004356710.2GHRHR, IGFBP1, IGFBP3
15growth hormone secretionGO:003025210.2GHRH, GHRHR, GHRL
16positive regulation of MAPK cascadeGO:004341010.2IGF1, IGF2, IGFBP3
17hormone-mediated signaling pathwayGO:000975510.2GHR, GHRL, TRH
18adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.1GHRH, GHRHR, GNAS
19response to nutrientGO:000758410.1SST, SSTR1, SSTR2
20positive regulation of cAMP biosynthetic processGO:003081910.1GHRH, GHRHR, GNAS
21cellular response to estradiol stimulusGO:007139210.1SSTR1, SSTR2, SSTR5
22somatostatin signaling pathwayGO:003817010.1SSTR1, SSTR2, SSTR5
23positive regulation of growth hormone secretionGO:006012410.1GHRH, GHRHR, GHRL
24digestionGO:000758610.1SST, SSTR1, SSTR2
25G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGO:000718710.0SSTR1, SSTR2, SSTR5
26positive regulation of insulin-like growth factor receptor signaling pathwayGO:00435689.9GH1, GHRH, GHRHR, IGF1, IGFBP3
27positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.9GH1, GHR, IGF1, IGF2
28neuropeptide signaling pathwayGO:00072189.6POMC, SSTR1, SSTR2, SSTR5
29regulation of multicellular organism growthGO:00400149.6GHR, IGF1, PRL
30positive regulation of multicellular organism growthGO:00400189.6GH1, GHR, GHRH, GHRHR, GHRL
31cell-cell signalingGO:00072679.1GHRH, GPR101, POMC, SST, SSTR1, SSTR2
32negative regulation of cell proliferationGO:00082858.8IGF1, IGFBP3, MEN1, SST, SSTR1, SSTR2
33cellular protein metabolic processGO:00442678.6GHRL, IGF1, IGF2, IGFBP1, IGFBP3, POMC
34G-protein coupled receptor signaling pathwayGO:00071868.2GHRHR, GHRL, GNAS, GPR101, SST, SSTR1

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1prolactin receptor bindingGO:000514810.5GH1, PRL
2growth hormone-releasing hormone activityGO:001660810.5GHRH, GHRL
3insulin-like growth factor I bindingGO:003199410.4IGFBP1, IGFBP3
4insulin-like growth factor II bindingGO:003199510.4IGFBP1, IGFBP3
5insulin-like growth factor receptor bindingGO:000515910.1GNAS, IGF1, IGF2
6somatostatin receptor activityGO:00049949.8SSTR1, SSTR2, SSTR5
7neuropeptide bindingGO:00429239.8SSTR1, SSTR2, SSTR5
8hormone activityGO:00051798.5GH1, GHRH, GHRL, IGF1, IGF2, POMC

Sources for Acromegaly

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet